“A NOVEL RNA INTERFERENCE THERAPY TO REDUCE CARDIOVASCULAR RISK BY LOWERING LIPOPROTEIN(A) LEVELS USING THE LEPODISIRAN AGENT”. 2026. Journal of Multidisciplinary Sciences and Innovations 5 (03): 1550-53. https://doi.org/10.55640/.